The acquisition of Croatian Jadran-Galenski Laboratorij’s (JGL) Russian D-Panthenol and women’s health portfolio enables Egis to support people’s health with products of the highest standards. In addition to the widely acknowledged quality of the products, Egis brand provides further guarantee for world-class expertise.

“Our more than 60 years of cooperation established exceptionally close relationship with Russia. This is the foundation of our commitment to provide the latest therapies, products of the highest quality for a wider group of people in Russia” – István Hodász, CEO at Egis commented.

The transaction includes the transfer of five presentations of popular skin repair and wound healing D-Panthenol, which is the second largest brand in the Russian dexpanthenol market. The product has a strong fit with Egis’ current operational model and existing portfolio in Russia. Predicted expansion is supported by Egis’ traditionally close relationship with Russian healthcare professionals as well as Russian patients’ confidence in the quality of its products.

Egis, building on its established expertise, also acquired JGL’s gynecology portfolio (namely Vagilac – probiotic capsule form for the prevention of disorders of the vaginal flora and liquid soap and gel forms for intimate care, Feminal  - a dietary supplement for the relief of menopause symptoms and Folacin – a folic acid product).  The transaction allows the company to provide a wider brand portfolio for Russian patients in the field of prevention and treatment of gynecological disorders.